-
Professor Xu Bing: The treatment of FL should have a "strategic vision", and comprehensive consideration of treatment options is the key| the 7th International Summit Forum on Anti-leukemia and Lymphoma
Time of Update: 2023-01-05
Follolar lymphoma (FL) is the most common indolent non-Hodgkin lymphoma, and first-line standard therapy significantly improves the prognosis of patients with FL, but FL is difficult to cure, and surv
-
Envolimab has been recommended by 6 CSCO guidelines and has unlimited prospects in the field of multitumors
Time of Update: 2023-01-05
*For medical professionals onlyCongratulations to Envolimab for winning the 2022 CSCO Ovarian Cancer Guidelines recommendation!Simcere Pharmaceutical, Sidi Pharmaceutical, and Corning Jereh Biopharma
-
Cutting-edge treatment of the most common childhood brain tumors, the latest research to find key targets
Time of Update: 2023-01-05
▎WuXi AppTec Content Team Editor Recently, scientists at McMaster University in Canada found that a catalytic enzyme involved in regulating the pyrimidine synthesis process is expected to become a key
-
The team of Xu Lin and Yin Rong of the Cancer Hospital of Nanjing Medical University discovered a new strategy for early screening of lung cancer
Time of Update: 2023-01-05
On November 8, 2022, the team of Xu Lin and Yin Rong of Nanjing Medical University Cancer Hospital published a title in the American Journal of Respiratory and Critical Care Medicine Multi-dimensional cell-free DNA fragmentomic assay for detection of early-stage lung cancer [3].
-
Medical interview with Professor Li Yuntao: comprehensively interpret the clinical significance of sentinel lymph node biopsy and formulate the best treatment plan for breast cancer
Time of Update: 2023-01-05
03Follow guideline recommendations and continuously update clinical practiceThe Guidelines and Standards for the Diagnosis and Treatment of Breast Cancer of the Chinese Anti-Cancer Association (2022 Edition) [5] suggest that ALND can be exempted from ALND for breast-conserving patients who have not received neoadjuvant therapy and have negative clinical axillary lymph nodes, but 1~2 SLN macro metastases on pathological examination and will receive subsequent further adjuvant whole breast radiotherapy and systemic therapy.
-
2022 CSCO | Professor Zhou Caicun: Filling the gap to help the future, progress in HER2 diagnosis and treatment and new breakthroughs in ADC drugs
Time of Update: 2023-01-05
Novel ADC combined with immunization targeting TROP2 is expected to advance the treatment status of patients with high expression of PD-L1Professor Zhou CaicunShanghai Pulmonary Hospital Affiliated to Tongji UniversityThe TROPION-Lung02 study explored the efficacy and safety of Dato-DXd+ pembrolizumab ± platinum-containing chemotherapy (dual or triple-drug) for metastatic NSCLC.
-
Golden Exercise Time is out! Did you choose the right one? Two major studies found that exercising at 8-10 a.m. reduced the risk of cancer by 27% and stroke by 17%
Time of Update: 2023-01-05
This article is the original of Translational Medicine Network, please indicate the source for reprintingWritten by SophiaExercise and cancer 01 In this study, the researchers observed that the overall protective effect of recreational and home physical activity on cancer may vary depending on the time of day of the activity.
-
2022 CSCO Professor Hu Yi: Optimized management, accurate future, full management of immunotherapy and the road to the future
Time of Update: 2023-01-05
The 25th National Congress of Clinical Oncology and the 2022 CSCO Annual Conference were held in Beijing on November 5. The conference focuses on the clinical frontier of oncology, invites well-known
-
2022 CSCO | Professor Wang Baocheng: Heading to heights, exploring the unknown, and looking forward to immunotherapy unlocking more surprises
Time of Update: 2023-01-05
The development of a new generation of new anti-tumor drugs is also one of the important ideas to overcome immune drug resistance, including new immune checkpoint inhibitors, oncolytic viruses, cellular immunotherapy, etc.
-
Prostate: How do ATM and BRCA2 metastasis-castration-resistant prostate cancers respond to statin and PARP inhibitors?
Time of Update: 2023-01-05
PARP (poly(ADP-ribose) polymerase) inhibitors (PARPi) are the standard of care for patients with metastatic castration-resistant prostate cancer (mCRPC) where specific variants are present in the DNA damage repair (DDR) pathway, but patients with ATM and BRCA2 variants may treat PARPi differently.
-
The treatment of brain metastases of Round Table lung cancer has made excellent progress, and the survival benefit of patients is expected to be prolonged
Time of Update: 2023-01-05
04Professor Wang Dong: Improve the intrathecal injection treatment plan and improve the quality of life of patientsThe treatment of patients with meningeal metastasis of lung cancer and cerebrospinal fluid detection of tumor cells is very difficult.
-
BJC| "dEGFR39 digital PCR panel test" to facilitate liquid biopsy of lung cancer
Time of Update: 2023-01-05
In the era of precision medicine, accurate diagnosis is the prerequisite for precision treatment. "dEGFR39" digital PCR panel detection reagent (Epbay Bio) detects 39 mutation sites of EGFR in a singl
-
What are the clinical manifestations of lung cancer in the early stages of the Global Lung Cancer Awareness Month?
Time of Update: 2023-01-05
Figure 1 The population screened for lung cancer selected the clinical manifestations of lung cancer as central lung cancer May present with clinical signs and symptoms, including cough, sputum production, hemoptysis, stridor, chest tightness, shortness of breath, chest pain, hoarseness, dysphagia, superior vena cava syndrome, diaphragmatic paralysis, pleural and pericardial effusion, Pancoast syndrome, etc.
-
Professor Li Xiaoqiu: Pathology as the basis, science and technology helped: a brief discussion on the dilemma and hope of pathological diagnosis of lymphoma The 7th Anti-leukemia and Lymphoma International Summit Forum
Time of Update: 2023-01-05
Professor Li Xiaoqiu In recent years, the diagnosis and treatment of lymphoma has increasingly emphasized the value of genetics and molecular biology, and the classification and diagnostic criteria of WHO lymphoma have also changed, which of course is inseparable from the development of laboratory diagnostic technology, from fluorescence in situ hybridization technology (FISH) that can only detect a single gene to high-throughput next-generation sequencing of multiple genes at the same time.
-
SCI Window "Nature" published the Chinese people to draw the endometrial cancer development and development cell map
Time of Update: 2023-01-05
。 Recently, Chen Xiaojun of the Affiliated Obstetrics and Gynecology Hospital of Fudan University and Zhao Bing, State Key Laboratory of Genetic Engineering of Fudan University, published a paper in Nature Communications, which mapped the dynamic map of different cell subsets of cells during the transition from normal endometrial to endometrioid carcinoma through single-cell transcriptomic analysis, revealing the potential cell origin and pathological development process of endometrium-like carcinoma[1].
-
The tumor that has the most impact on nutrition! Nutrition therapy for patients at different stages of treatment should pay attention!
Time of Update: 2023-01-05
Image source: 123RFClinical diagnostic criteria for malnutrition in patients with gastric cancerFor the clinical diagnosis of malnutrition in gastric cancer patients, it is recommended to refer to the Consensus on Malnutrition Assessment (Diagnosis) Standards (GLIM) initiated by the Global (Nutrition) Leadership Initiative.
-
Professor Chen Ping talked about the hard power of the three generations of ALK-TKI lorlatinib
Time of Update: 2023-01-05
ALK kinase domain ATP-binding pocket ALK-TKI*A：TAE684； B: crizotinib ; C: ceritinib ; D: Alletinib; E: lorlatinib ; F: BurglitinibFirst-line benefit, lorlatinib breakthrough extended median PFS to more than 3 yearsLolatinib's compact macrocyclic amide structure and smaller molecular weight increase anti-tumor activity, making lorlatinib show good efficacy in the first-line treatment of ALK+NSCLC patients, and fully demonstrated in the CROWN study.
-
BJC: Middle-aged teeth are not good, be careful of the "cancer king" to find! Chinese scientists analyzed data from nearly 6 million people and found that periodontitis under 50 years of age was associated with a 56% increased risk of pancreatic cancer
Time of Update: 2023-01-05
The study found that people with mild tooth inflammation (gingivitis, pericoronitis, stomatitis and mucositis) and periodontitis had a higher risk of pancreatic cancer (35% and 56% higher, respectively) in people under 50 years of age, including information on dental diseases in the Swedish Dental Health Register and the incidence of pancreatic cancer among these people.
-
【CELL DEATH DIS】 The Southern Medical University team revealed for the first time the role of Myo1b in the regulation of autophagy and angiogenesis in colon cancer cells
Time of Update: 2023-01-05
Recently, Yihong Chen, Nanzhu Xu, Chang Hong of Southern Medical University as the first authors, and Professor Jueyu Zhou as the corresponding author, published a report entitled "Myo1b promotes tumor progression and angiogenesis by inhibiting autophagic degradation of HIF-1α in colorectal" in Cell Death & Disease cancer".
-
Clinical overview of next-generation CAR-T cell therapy
Time of Update: 2023-01-05
Advances in immunology and molecular engineering have led to the construction of a new generation of CAR-T cells armed with a variety of molecular mechanisms, including additional co-stimulatory domains, safety switches, immune checkpoint regulation, cytokine expression, or knockout of therapeutic interfering molecules.
